分子バイオマーカーと診断のジャーナル

Biomarker Development for COVID-19 Point-of-Care Diagnosis

Abstract

Martina Kandulski*

Coronavirus disease is a highly contagious infection that has triggered a pandemic in 2019. Early disease diagnosis has been identified as one of the most important approaches to reducing pathological impact and infection spread. Point-of-care tests have proven to be valuable analytical tools, particularly lateral flow immunoassays. Biosensors have grown in popularity in recent years. These are simple but highly sensitive and precise analytical devices made up of a selective molecule like an antibody or antigen and a sensor platform. Biosensors would be a more advanced alternative to current point-of-care tests and standard laboratory methods for COVID-19 diagnosis. Recent breakthroughs in COVID-19 point-of-care diagnostic tests, as well as the development of biosensors for specific antibodies and viruses.